Xeris Biopharma Holdings Inc. (XERS) exhibits 45.0% gross margins and 16.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 83.1x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 8.5% operating margin and 16.0% ROIC, outpacing sector cost of capital.
ROIC: 16.0% // GM: 45.0%YoY revenue trajectory of +43.7% paired with 1.46% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +43.7% // FCF YLD: 1.46%Altman Z-Score of 2.11 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.11 // F-SCORE: 7/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 83.1xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $10.75 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 0.2% net margins.
NET MARGIN: 0.2% // D/E: 8.50x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for XERS & activate live FRED threshold breach alerts.